摘要
Seven-transmembrane receptors (7TMRs), the most common molecular targets of modern drug therapy, are critically regulated by β-arrestins, which both inhibit classic G-protein signaling and initiate distinct β-arrestin signaling. The interplay of G-protein and β-arrestin signals largely determines the cellular consequences of 7TMR-targeted drugs. Until recently, a drug's efficacy for β-arrestin recruitment was believed to be proportional to its efficacy for G-protein activities. This paradigm restricts 7TMR drug effects to a linear spectrum of responses, ranging from inhibition of all responses to stimulation of all responses. However, it is now clear that ‘biased ligands’ can selectively activate G-protein or β-arrestin functions and thus elicit novel biological effects from even well-studied 7TMRs. Here, we discuss the current state of β-arrestin-biased ligand research and the prospects for β-arrestin bias as a therapeutic target. Consideration of ligand bias might have profound influences on the way scientists approach 7TMR-targeted drug discovery. Seven-transmembrane receptors (7TMRs), the most common molecular targets of modern drug therapy, are critically regulated by β-arrestins, which both inhibit classic G-protein signaling and initiate distinct β-arrestin signaling. The interplay of G-protein and β-arrestin signals largely determines the cellular consequences of 7TMR-targeted drugs. Until recently, a drug's efficacy for β-arrestin recruitment was believed to be proportional to its efficacy for G-protein activities. This paradigm restricts 7TMR drug effects to a linear spectrum of responses, ranging from inhibition of all responses to stimulation of all responses. However, it is now clear that ‘biased ligands’ can selectively activate G-protein or β-arrestin functions and thus elicit novel biological effects from even well-studied 7TMRs. Here, we discuss the current state of β-arrestin-biased ligand research and the prospects for β-arrestin bias as a therapeutic target. Consideration of ligand bias might have profound influences on the way scientists approach 7TMR-targeted drug discovery. a ligand that, by binding a receptor, increases that receptor's activity. a ligand that binds a receptor without stimulating any activity. Also known as a ’blocker’ because of its ability to prevent binding of other ligands and, therefore, block agonist-induced activity. when ligand binding stimulates or inhibits all receptor functions to an equal extent; thus, the relative efficacy of a ligand for any signal is identical to the relative efficacy of that ligand for any other signal. ligand stimulation of multiple receptor activities with different relative efficacies for different signals; thus, the selectivity of the ligand is not absolute. an antagonist that, in addition to blocking agonist effects, reduces receptors’ basal, constitutive activity. the ability of a ligand to selectively stimulate a subset of a receptor's activities. Such ligands are known as ‘biased ligands’, ‘biased agonists’ or ‘functionally selective agonists’. a special case of an antagonist that neither stimulates any signals nor inhibits intrinsic receptor activity. an agonist that results in a sub-maximal response, even when receptors are fully occupied. Partial agonists can also function as ‘blockers’ by preventing the binding of more-robust agonists. ligand stimulation of one receptor activity without any stimulation of another known receptor activity.